The risk of sentinel lymph node (SLN) metastasis is directly related to the Breslow thickness of the primary lesion. Among patients with thin melanoma, the risk of SLN metastasis is <5%. 3 Various investigators have attempted to identify characteristics of thin melanomas that are associated with a significant risk of SLN metastasis. In an analysis of 1250 patients with thin melanoma who had a SLN biopsy, Han et al. found that Breslow depth >0.75 mm, Clark's Level ≥IV, and ulceration (but not mitotic rate) were independent predictors of SLN metastasis. 4 Two studies have demonstrated an association between SLN positivity and an elevated mitotic rate, 5, 6 although increased mitotic activity is more commonly associated with poorer survival. [7] [8] [9] Based on these reports, the presence of ulceration and/or mitotic activity (in conjunction with Patients with a transected melanoma <1 mm in Breslow thickness with no other adverse features may undergo SLN biopsy due to the assumption that they are at higher risk of SLN metastasis. Because of the ubiquity of shave biopsy, these patients represent a significant proportion of newly diagnosed melanoma patients. Indeed, the presence of a positive deep margin at biopsy occurs in more than half of patients with clinically localized melanoma 10 . Because the vast majority of melanoma patients have early disease, and because a significant proportion of these will have a positive deep margin, the medical and economic implications of using DM positivity as an indication for SLN staging are potentially enormous. For this reason, we asked whether patients with thin melanoma with a (+)DM on initial biopsy are at higher risk of SLN metastasis than DM (−) patients. If so, SLN may be justified in a significant percentage of patients with thin but transected melanoma. 
| MATERIALS AND METHODS

| RESULTS
A total of 1413 patients with thin melanoma who had a SLN biopsy were identified. Of these, 1129 had complete margin data to permit comparison of those with positive versus negative DMs (see Figure 1 for specific exclusion criteria). The mean age of the patients was 52.2 +/− 15.1 years, and about half were male (606/1129 [53.6%]). In
FIGURE 1
The study population was derived from 1413 patients identified from two institutional databases who underwent SLN staging for thin melanoma and had a known deep margin status. The reasons for exclusion of cases are illustrated the 586 patients for whom information regarding the initial biopsy technique was available, 325 patients (55%) were diagnosed using a shave biopsy (Table 1) . Among all patients, the initial biopsy resulted in 
and mitotic rate ≥1/mm 2 were also statistically significantly associated with SLN involvement. None of the other factors including age, sex, and ulceration were associated with SLN metastasis (Table 2) . On multivariate analysis, only Breslow thickness >0.75 mm and Clark's Level IV were independent predictive factors for SLN metastasis (Table 3) .
| DISCUSSION
There Lowe et al evaluated the impact of shave biopsy on patients with thin melanoma. Similar to our study, there was no difference in the incidence of SLN metastasis in 260 patients stratified by deep margin status. 12 Involvement of the DM on initial biopsy was not associated with an increased risk for SLN metastasis. This finding alone should not prompt regional nodal staging in an otherwise low-risk patient.
Shave biopsies are more likely to result in a (+) DM when compared to punch or excision biopsies. 10 Shave biopsies remain the most Nevertheless, very few tumors are upstaged when wide excision is performed following a shave biopsy with a (+) DM. 13, 14 In recent updates to the NCCN guidelines and American Joint
Commission on Cancer (AJCC) staging criteria, elevated mitotic rate has supplanted Clark's Level in the T-staging of thin melanoma. Several studies have demonstrated a correlation between elevated mitotic rate and a lower survival probability in patients with early melanoma. 7, 9, 15 The association between mitotic rate and SLN metastasis is less well established, however, with some studies demonstrating a significant association, 5, 6 and others showing none. 4, 16 In our study, an elevated mitotic rate was common in this group of patients with thin melanoma undergoing SLN biopsy (655/994 [65.9%]), including a significant proportion of patients with melanoma ≤0.75 mm thick. While elevated mitotic rate was significantly associated with SLN metastasis on univariate analysis, significance was lost on multivariate analysis.
Conversely, Clark's Level IV, present in a similar proportion of study patients (60%), retained a significant association with SLN metastasis on both univariate and multivariate analysis.
Current NCCN guidelines do not recommend SLN staging for melanomas ≤0.75 mm in Breslow depth. The reason that SLN biopsy was performed in the patients in our study with melanoma ≤0.75 mm in Breslow could not be accurately ascertained in this retrospective study.
However, most of these patients had other high-risk features, including ulceration and/or mitotic activity, and those with a (+) DM on initial biopsy. Regardless, the incidence of SLN metastasis was still quite low at 6/498 (1.2%). These results suggest that SLN staging is not appropriate in these patients, even in the presence of a (+) DM on initial biopsy.
The markedly low incidence of SLN metastasis in patients with tumors ≤0.75 mm in thickness in our study approximates the incidence of 1.4% in a study examining the cost-effectiveness of SLN biopsy for patients with thin melanoma. 17 The 
| CONCLUSIONS
Our data suggest that in patients with thin melanoma and no residual lesion suspicious for more advanced disease, DM involvement alone should not be used as a criterion to perform SLN staging.
ACKNOWLEDGMENT
The authors thank Oren Misholy (Memorial Sloan Kettering Cancer
Center) for assistance with data collection and database management and Katherine Panageas (Memorial Sloan Kettering Cancer Center) for 
